Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Saline versus heparin lock for totally implantable venous access ports in cancer patients
2009-013620-22Phase 3Completed
- Sponsor
- ASL Biella
- Start
- Nov 2009
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of heparin and sodium chloride in cancer (2 arms), sponsored by ASL Biella. Primary endpoint: Port failure for lumen occlusion. Started Nov 2009; status: completed.
02
Drugs
heparinsodium chloride
03
Conditions
cancer
Beyond the preview
Go deeper on 2009-013620-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-013620-22.